EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Perspectives for Targeting Ezrin in Cancer Development and Progression

Jean Carlos Lipreri da Silva, Hugo Passos Vicari, João Agostinho Machado-Neto

Future Pharmacology · 09.01.2023 · 3 (1) · 61-79

DOI: 10.3390/futurepharmacol3010005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Pharmacology, online erschienen am 09.01.2023. Verfasst von Jean Carlos Lipreri da Silva und 2 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: São Paulo Research Foundation, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Brasil (CAPES).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent advances have been made in understanding molecular markers involved in cancer malignancy, resulting in better tumor staging and identifying new potential therapeutic targets. Ezrin (EZR), a member of the ezrin, radixin, moesin (ERM) protein family, is essential for linking the actin cytoskeleton to the cell membrane and participates in the signal transduction of key signaling pathways such as Rho GTPases and PI3K/AKT/mTOR. Clinical and preclinical studies in a wide variety of solid and hematological tumors indicate that (i) EZR is highly expressed and predicts an unfavorable clinical outcome, and (ii) EZR inhibition reduces proliferation, migration, and invasion in experimental models. The development of pharmacological inhibitors for EZR (or the signaling mediated by it) has opened a new round of investigation, but studies are still limited. The scope of the present review is to survey studies on the expression and clinical impact of EZR in cancer, as well as studies that perform interventions on the function of this gene/protein in cancer cells, providing proof-of-concept of its antineoplastic potential.

Förderung

  • São Paulo Research Foundation
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Brasil (CAPES)

Zitieren

APA

Silva, J. C. L. D., Vicari, H. P., & Machado-Neto, J. A. (2023). Perspectives for Targeting Ezrin in Cancer Development and Progression. Future Pharmacology, 3(1), 61-79. https://doi.org/10.3390/futurepharmacol3010005

Vancouver

Silva JCLD, Vicari HP, Machado-Neto JA. Perspectives for Targeting Ezrin in Cancer Development and Progression. Future Pharmacology. 2023;3(1):61-79. doi:10.3390/futurepharmacol3010005

BibTeX
@article{Silva2023,
  author = {Silva, Jean Carlos Lipreri da and Vicari, Hugo Passos and Machado-Neto, João Agostinho},
  title = {Perspectives for Targeting Ezrin in Cancer Development and Progression},
  journal = {Future Pharmacology},
  year = {2023},
  volume = {3},
  number = {1},
  pages = {61--79},
  doi = {10.3390/futurepharmacol3010005}
}
Kostenlos starten →